ARCH Venture Partners and TCGX led a $73.9m Series C round in Arbor Biotechnologies.

ARCH Venture Partners, a venture capital firm, and TCGX, a science-driven investment firm, led a $73.9m Series C round in Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, with participation from QIA, Partners Investment, Revelation Partners, and Kerna Ventures, Ally Bridge Group, Arrowmark Partners, Deep Track Capital, Piper Heartland Healthcare Capital, Surveyor Capital, Temasek, T. Rowe Price Associates and Vertex Pharmaceuticals Incorporated. "Arbor is developing a differentiated portfolio with first-in-class potential to deliver on the promise of CRISPR-based genetic medicines. Arbor has established a track record of pipeline focus, coupled with execution and capital efficiency, to yield strong preclinical data supporting its pipeline. We are impressed with the team’s progress to date and are proud to support the advancement of these programs," Keith Crandell, ARCH Venture Partners Co-Founder and Partner.